viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals highlights new research showing Vistitan's effectiveness at treating glaucoma

A new study shows that Vistitan is the most effective topical treatment to reduce intraocular pressure

Vistitan reduces the pressure inside the eyes of patients with glaucoma

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCMKTS:AQSZF) updated shareholders on Friday on new research that highlights the effectiveness of the company’s Vistitan product in treating glaucoma. 

Results presented at the American Academy of Opthamology in San Franciso showed that bimatoprost 0.03%, marketed as Vistitan, is the most effective topical treatment to reduce intraocular pressure currently available for the eye disease. 

Vistitan reduces the pressure inside the eyes of patients with glaucoma and was first marketed by the pharmaceutical giant Sandoz. 

READ: Aequus Pharmaceuticals returns to revenue growth in second quarter

The study was conducted by Dr Paul Harasymowycz to assess the effectiveness of the opthalmic drug latanoprostene bunod compared to other treatments for intraocular pressure reduction after three months. 

Harasymowycz and his team found that bimatoprost 0.03% is the most successful treatment to reduce pressure and mitigate the risk of glaucoma. 

“In treating a disease where every millimetre of ocular pressure control is important, the data continues to support the use of Vistitan over the competition due to its effective bimatoprost 0.03% formulation,” said Ian Ball, CCO of Aequus in a statement.  

“This study adds to a growing body of evidence that Vistitan, the only bimatoprost 0.03% formulation currently marketed in Canada, is the most effective product available for treating glaucoma and is the cornerstone of our rapidly expanding ophthalmology franchise in Canada.” 

Vistitan is currently the only marketed version of 0.03% bimatoprost ophthalmic solution for glaucoma in Canada. 

Shares of Aequus traded at C$0.13 in Canada on Friday morning and US$0.10 on OTC markets. 

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.125 CAD

Market: TSX-V
Market Cap: $13.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...


Aequus Pharmaceuticals receives approval for Evolve Gel lubricating eye...

Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye...

1 week, 3 days ago

2 min read